HomeCompareTKYVY vs ABBV

TKYVY vs ABBV: Dividend Comparison 2026

TKYVY yields 31.75% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TKYVY wins by $44.0K in total portfolio value
10 years
TKYVY
TKYVY
● Live price
31.75%
Share price
$6.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$146.3K
Annual income
$20,332.14
Full TKYVY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TKYVY vs ABBV

📍 TKYVY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKYVYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKYVY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKYVY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKYVY
Annual income on $10K today (after 15% tax)
$2,698.41/yr
After 10yr DRIP, annual income (after tax)
$17,282.32/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $3,773.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKYVY + ABBV for your $10,000?

TKYVY: 50%ABBV: 50%
100% ABBV50/50100% TKYVY
Portfolio after 10yr
$124.3K
Annual income
$22,551.95/yr
Blended yield
18.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TKYVY
No analyst data
Altman Z
0.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKYVY buys
0
ABBV buys
0
No recent congressional trades found for TKYVY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKYVYABBV
Forward yield31.75%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$146.3K$102.3K
Annual income after 10y$20,332.14$24,771.77
Total dividends collected$102.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TKYVY vs ABBV ($10,000, DRIP)

YearTKYVY PortfolioTKYVY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,875$3,174.60$11,550$430.00+$2.3KTKYVY
2$18,962$4,116.48$13,472$627.96+$5.5KTKYVY
3$25,548$5,257.91$15,906$926.08+$9.6KTKYVY
4$33,956$6,620.46$19,071$1,382.55+$14.9KTKYVY
5$44,557$8,223.86$23,302$2,095.81+$21.3KTKYVY
6$57,761$10,085.28$29,150$3,237.93+$28.6KTKYVY
7$74,023$12,218.70$37,536$5,121.41+$36.5KTKYVY
8$93,839$14,634.31$50,079$8,338.38+$43.8KTKYVY
9$117,746$17,338.22$69,753$14,065.80+$48.0KTKYVY
10$146,321$20,332.14$102,337$24,771.77+$44.0KTKYVY

TKYVY vs ABBV: Complete Analysis 2026

TKYVYStock

Türkiye Vakiflar Bankasi Türk Anonim Ortakligi, together with its subsidiaries, provides corporate, commercial, small business, retail, and investment banking services in Turkey and internationally. It offers time and demand deposits, accumulating accounts, repos, spot loans, foreign currency indexed loans, consumer loans, automobile and housing loans, working capital loans, discounted bills, overdraft facilities, gold loans, foreign currency loans, Eximbank loans, pre-export loans, ECA covered financing, letters of guarantee, letters of credit, export factoring, acceptance credits, and draft facilities. The company also provides forfeiting, leasing, forwards, futures, salary payments, investment accounts, cheques, safety boxes, tax collections, bill payment, and payment order services, as well as insurance products. In addition, it offers foreign trade transactions, cash management, factoring, credit cards, investment products, leasing, and other banking products to its corporate, commercial, and retail customers. Further, the company provides small business banking services, including overdraft accounts, POS machines, credit cards, cheque books, TL and foreign currency deposits, Internet banking and call-center, debit card, and bill payment to enterprises in retail and service sectors. Additionally, it offers capital market transactions; issues capital market tools; purchases and sells marketable securities; and provides investment consultancy and portfolio management services, as well as invests in marketable debt and equity securities, and gold and other precious metals. As of December 31, 2021, the company operated a network of 936 branches in Turkey, as well as 4 foreign branches located in New York, Bahrain, Qatar, and Erbil. Türkiye Vakiflar Bankasi Türk Anonim Ortakligi was founded in 1954 and is headquartered in Istanbul, Turkey. Türkiye Vakiflar Bankasi Türk Anonim Ortakligi is a subsidiary of Ministry of Treasury and Finance.

Full TKYVY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TKYVY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKYVY vs SCHDTKYVY vs JEPITKYVY vs OTKYVY vs KOTKYVY vs MAINTKYVY vs JNJTKYVY vs MRKTKYVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.